Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Stock: A Value Gem With Upside Catalysts

The stock is lingering around the initial support level of $0.25. After this, the following support is at the zone of $0.23. Up until the time the TTNP stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 55.98 on the daily chart, and this may be a cause for concern. In case the price goes below $0.23 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $0.28 level may cause a pull-back move approaching $0.3 mark.

Titan Pharmaceuticals, Inc. (TTNP) is most likely going to rise 3300 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $1 as 12-month high price target. This represents a whopping 300 percent increase from the current trading price of shares. The 52-week median price target given by the analysts is $1, which means a return possibility of 300 percent in comparison with the closing price of the stock of $0.25 in recent trading session. The lowest price set for the stock is $1 which is just above 300 percent from TTNP share’s price at the end of session.

Let’s take a glimpse at some insider activity at Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and observe the pattern. The earliest insider trade happened on 09/21/2018. Rubin Marc gathered a total of 400 thousand shares of the firm at average share price of $0.25. The total amount for the purchase was set at $100 thousand. On completing this exchange, the Executive Chairman account balance was 556.32 thousand shares. The stock grew 8 percent from that insider purchase. On 09/21/2018, MCNAB JAMES R, Director, did a purchase of 200 thousand shares at a price of $0.25 per share. This increased 50 thousand shares to the insider’s fortune and the stock experienced a 8 percent rally in price since the news became public. This exchange saw 300 thousand shares get into the Director account. On 09/21/2018, Director MACFARLANE M DAVID recorded a purchase transaction valued at $20 thousand. The purchase at $0.25 a share has added 80 thousand shares into the insider’s portfolio position. Meanwhile, shares price witnessed 8 percent increase since the transaction reporting date. The company insider is left with 102.28 thousand shares remaining in the account. Akers Joseph A, who works as Director at the company, performed a purchase of 200 thousand shares in a transaction worth $50 thousand. The acquisition recorded on 09/21/2018 was priced at $0.25 per share. The stock price soared 8 percent since the transaction. Akers Joseph A currently holds a stake of 213 thousand in TTNP stock which is worth $53.25 thousand after the insider buying.

In the recent trading session, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) shares lost -4.4% or -0.01 points to reach at $0.25 with a thin trading volume of 2.82 million shares. It opened the trading session at $0.278, the shares rose to $0.285 and dropped to $0.25, the range by which the price of stock traded the whole session. The company now has a market cap of $19.38 million and currently has 73.7 million outstanding shares. Titan Pharmaceuticals, Inc. (TTNP) stock has accumulated 60.37 percent of market value in 21 trading days.

Stock analysts at Maxim Group, assumed coverage of shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) with Buy recommendation, according to their opinion released on June 26. ROTH Capital analysts have downgraded their rating of TTNP shares from Buy to Neutral in a separate flash note to investors on November 10.

TTNP stock’s trailing 3-year beta is 1.29, meaning there will be a greater rate of return, although posing a higher risk. The part of a firm’s profit given to each outstanding share of regular stock was -$1.53 share in the trailing 52 weeks. The stock’s value surged 35.5 percent year to date (YTD) compared to a decline of -79.89 percent in 52 week’s period. The firm’s shares are still trading -89.74 percent below its 1-year high of $2.45 and 77.07 percent up from 52-week low of $0.14. The average consensus ranking on the company is 2, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a buy.

Titan Pharmaceuticals, Inc. has a 71.7% gross profit margin.

Past records have indicated that shares in Titan Pharmaceuticals, Inc. declined on 12 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of TTNP’s Q4 earnings on March 20. Analysts are predicting revenue to suffer decline of -25.6 percent to $920M in the financial fourth quarter, while EPS will soar by about -72.41 percent to -$0.08 per share. In the last quarter, it’s earnings of -$0.18 per share came worse than the -$0.08, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $947000, topping the $700000 analysts had expected. Earnings are seen to rise by 80.8 percent this year, 77.5 percent in the coming year.